GlassScriptPhysician profile
Andrew S Weber
NPI 1356372544
$4,648.35
in general payments reported to CMS, 2019-2025
21 companies · $627 in 2025
The $627 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $778 · 2020: $481 · 2021: $535 · 2022: $668 · 2023: $730 · 2024: $829 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,125 · Education: $61.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,124.79 |
| Education | $61.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,612.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $971.03 | 2019-2025 | Airsupra, Breztri, Symbicort |
| Philips North America LLC | $606.30 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
| Boehringer Ingelheim Pharmaceuticals, INC. | $348.80 | 2019-2024 | Ofev |
| Actelion Pharmaceuticals US, INC. | $256.63 | 2020-2024 | Opsumit, Uptravi |
| Electromed, INC. | $198.19 | 2019-2024 | Smartvest |
| Amarin Pharma, INC. | $121.61 | 2019-2021 | |
| Viatris Specialty LLC | $112.62 | 2025 | Yupelri |
| Verona Pharma, INC. | $81.82 | 2025 | Ohtuvayre |
| Genzyme Corporation | $71.53 | 2022-2024 | |
| Abbvie INC. | $45.54 | 2024 | |
| Arbor Pharmaceuticals, INC. | $32.57 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $30.44 | 2021 | |
| Pfizer INC. | $29.03 | 2022-2024 | |
| Mallinckrodt Hospital Products INC. | $25.46 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $25.23 | 2024 | Keytruda |
| Janssen Pharmaceuticals, INC | $22.16 | 2022 | |
| Circassia INC. | $16.35 | 2019 | |
| Advanced Respiratory, INC | $13.95 | 2020 | |
| Eisai INC. | $13.49 | 2021 | |
| Exelixis INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.